Back to search results

Investigating HP 129Xe MRI in Lung Cancer Patients Receiving Radiation Therapy

This research study is looking at a new type of imaging scan called Hyperpolarized Xenon-129 Magnetic Resonance Imaging (HP 129Xe MRI) to see if it can help doctors understand and predict common side effects of radiation therapy in people with lung cancer. Instead of an injection, you would inhale the 129Xe gas for the scan. This study aims to see if HP 129Xe MRI can identify and predict a side effect called radiation pneumonitis (inflammation of the lungs caused by radiation) and if it can detect it before symptoms appear. The 129Xe tracer is investigational and not yet approved by the FDA. We are looking for up to 70 participants, including healthy volunteers and lung cancer patients.

Study design
This is an observational study with up to 70 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Safety and side effects will be measured throughout the study, which is expected to last an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06909201

Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity

Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~70 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:HP 129Xe MRI

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety and Adverse Events (AEs)
Measured over Through study completion; an average of 1 year

Conditions

Lung Cancer

Explore related trials

Lung Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Joshua Niedzielski · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Joshua Niedzielski, PHD
[email protected]
(713) 745-8946
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Postmenopausal (no menses in greater than or equal to 12 consecutive months).
History of hysterectomy or bilateral salpingo-oophorectomy.
Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).
History of bilateral tubal ligation or another surgical sterilization procedure.
Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject/Partner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Additionally, if female partners of male study participants become pregnant during study participation, the treating physician should be informed immediately.
Ability to understand and the willingness to sign a written informed consent document.

What this trial measures

  • Safety and Adverse Events (AEs)Through study completion; an average of 1 year

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0